

**ROSWELL PARK CANCER INSTITUTE CORPORATION
TECHNOLOGY TRANSFER COMMITTEE
OF THE BOARD OF DIRECTORS**

A meeting of the Technology Transfer Committee of the Board of Directors of Roswell Park Cancer Institute Corporation was held on Thursday November 16, 2017 at 8:30 a.m. in the Patrick Lee Conference Room, 9th Floor, Scott Bieler Clinical Services Center of the Institute.

Present: Nora. B. Sullivan – Chairperson
June W. Hoeflich
Kenneth Manning
Noah Rifkin
R. Buford Sears
Candace S. Johnson, PhD, President & Chief Executive Officer
Joseph Dunn, PhD

Excused: Michael L. Joseph, Chairman of the Board

Present by

Invitation: Michael B. Sexton, Esq., Chief Institute Operations Officer and General Counsel – Secretary
Gregory McDonald, Chief Financial Officer
Camille Wicher, Ph.D., Esq. MSN, RN, Vice President of Corporate Ethics and Research Subject Protection
Harl Tolbert, Director of Technology Transfer & Commercial Development
Betsy Doty, Administrator to the Board of Directors
Thomas Schwaab, MD, PhD, Chief of Strategy, Business Development and Outreach
Ericka N. Bennett, Esq., Associate General Counsel
Kristen Castner, Intellectual Property Manager
Patrick Emmerling, PhD, Senior Licensing Manager

Ms. Sullivan opened the meeting and thanked all for attending the meeting, and stated that she, and Board Chairman Michael Joseph would meet with RPCI leadership to discuss defining the roles of the Tech Transfer and Business Development committees.

Ms. Sullivan asked for a motion to approve the April minutes which was made by Mr. Manning and seconded by Mr. Rifkin. The motion was unanimously approved.

Mr. Tolbert provided an overview of Witness Cares, a program founded by RPCI employees Deborah Irwin, PhD, and Detric Johnson. Dr. Irwin and Ms. Johnson are requesting funding from the Committee; however they have not provided a specific funding proposal. Ms. Sullivan commented that the business plan was very well written. Mr. Emmerling discussed the entrepreneur education programs in which Dr. Irwin and Ms. Johnson have participated. Mr. Manning requested details concerning the funding proposal submitted to the board and Mr. Tolbert stated that a detailed proposal had not yet been provided.

Board members questioned whether the funding request was better suited for another committee or RPCI funding source. Board members expressed interest in the program, but stated that they would like Dr. Irwin and Ms. Johnson to provide a detailed request for funding. *Mr. Sears made a motion stating that the Committee endorses the idea in concept, but requires further details in order to vote on potential funding. He further moved that Ms. Sullivan and a few other members of the Committee work to resolve those issues. Mr. Manning seconded the motion. The motion was unanimously approved.*

Mr. Tolbert discussed a potential collaboration between the University of Rochester, the University at Buffalo and RPCI. The discussions are in very early stages and additional information will be provided as discussions progress.

Mr. Tolbert referred Committee members to the slides and board materials that provided details on the licenses recently completed by the office. Mr. Tolbert pointed out that one of RPCI's licensees, Tracon Pharmaceuticals, has started a Phase II trial.

Mr. Tolbert stated that it may be helpful for Committee members to receive more information on the differences and similarities in the missions of the Tech Transfer and Business Development Offices. Dr. Schwaab described the Global Biotechnology & Cancer Therapeutics, LLC ("GBTC") as a separate entity intended to assist in the commercialization of projects unrelated to those of RPCI faculty members. Dr. Schwaab stated that GBTC has its own governing board and scientific advisory committee. Mr. Sexton stated that GBTC is a separate entity that has a separate focus from the Tech Transfer Office. Ms. Sullivan stated that the Tech Transfer Committee charter likely needs to be updated.

There being no further business, the meeting was duly adjourned.

Respectfully submitted,


Michael B. Sexton, Esq.